The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Recombinant FVIII-Global Market Insights and Sales Trends 2025
Synopsis
Recombinant FVIII
The global Recombinant FVIII market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Recombinant FVIII in various end use industries. The expanding demands from the Teenagers and Adults, are propelling Recombinant FVIII market. 250 IU/bottle, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the 500 IU/bottle segment is estimated at % CAGR for the next seven-year period.
According to the Global Use of Medicines 2023 released by IQVIA Institute, the global drug expenditure in 2022 was about US$1.48 trillion (excluding COVID vaccine and treatment-related expenses), and it is predicted to grow at a rate of 3%-6% in the next few years. In terms of drug expenditure, this number in China was about 166 billion dollars in 2022. It is expected that the expenditure on medicines will increase in the next few years. From the perspective of demand, the trend of population aging, the increase of residents’ wealth and the improvement of health awareness will drive the demand for medicines.
Global Use of Medicines 2023 shows that the U.S. market spent about US$ 62.9 billion on medicines in 2022 on a net ex-factory basis. Overall growth slows as the Inflation Reduction Act (IRA) spends US$64 billion to reduce prescription drug prices, and the adoption of new treatments is expected to increase over the next few years. Besides, ex-factory discounts and rebates in drug distribution, the impact of patent expiration, and generic or biosimilar competition will also affect the U.S. pharmaceutical market.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Recombinant FVIII, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Recombinant FVIII market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Recombinant FVIII market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Recombinant FVIII sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Recombinant FVIII covered in this report include Bayer, Baxter, Comirnaty, Novo Nordisk, Green Cross and Sinocelltech, etc.
The global Recombinant FVIII market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Bayer
Baxter
Comirnaty
Novo Nordisk
Green Cross
Sinocelltech
Global Recombinant FVIII market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Recombinant FVIII market, Segment by Type:
250 IU/bottle
500 IU/bottle
1000 IU/bottle
2000 IU/bottle
Global Recombinant FVIII market, by Application
Teenagers
Adults
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Recombinant FVIII manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Recombinant FVIII in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Recombinant FVIII
The global Recombinant FVIII market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Recombinant FVIII in various end use industries. The expanding demands from the Teenagers and Adults, are propelling Recombinant FVIII market. 250 IU/bottle, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the 500 IU/bottle segment is estimated at % CAGR for the next seven-year period.
According to the Global Use of Medicines 2023 released by IQVIA Institute, the global drug expenditure in 2022 was about US$1.48 trillion (excluding COVID vaccine and treatment-related expenses), and it is predicted to grow at a rate of 3%-6% in the next few years. In terms of drug expenditure, this number in China was about 166 billion dollars in 2022. It is expected that the expenditure on medicines will increase in the next few years. From the perspective of demand, the trend of population aging, the increase of residents’ wealth and the improvement of health awareness will drive the demand for medicines.
Global Use of Medicines 2023 shows that the U.S. market spent about US$ 62.9 billion on medicines in 2022 on a net ex-factory basis. Overall growth slows as the Inflation Reduction Act (IRA) spends US$64 billion to reduce prescription drug prices, and the adoption of new treatments is expected to increase over the next few years. Besides, ex-factory discounts and rebates in drug distribution, the impact of patent expiration, and generic or biosimilar competition will also affect the U.S. pharmaceutical market.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Recombinant FVIII, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Recombinant FVIII market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Recombinant FVIII market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Recombinant FVIII sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Recombinant FVIII covered in this report include Bayer, Baxter, Comirnaty, Novo Nordisk, Green Cross and Sinocelltech, etc.
The global Recombinant FVIII market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Bayer
Baxter
Comirnaty
Novo Nordisk
Green Cross
Sinocelltech
Global Recombinant FVIII market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Recombinant FVIII market, Segment by Type:
250 IU/bottle
500 IU/bottle
1000 IU/bottle
2000 IU/bottle
Global Recombinant FVIII market, by Application
Teenagers
Adults
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Recombinant FVIII manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Recombinant FVIII in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Index1 Recombinant FVIII Market Overview
1.1 Recombinant FVIII Product Overview
1.2 Recombinant FVIII Market Segment by Type
1.2.1 250 IU/bottle
1.2.2 500 IU/bottle
1.2.3 1000 IU/bottle
1.2.4 2000 IU/bottle
1.3 Global Recombinant FVIII Market Size by Type
1.3.1 Global Recombinant FVIII Market Size Overview by Type (2018-2029)
1.3.2 Global Recombinant FVIII Historic Market Size Review by Type (2018-2023)
1.3.3 Global Recombinant FVIII Forecasted Market Size by Type (2024-2029)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Recombinant FVIII Sales Breakdown by Type (2018-2023)
1.4.2 Europe Recombinant FVIII Sales Breakdown by Type (2018-2023)
1.4.3 Asia-Pacific Recombinant FVIII Sales Breakdown by Type (2018-2023)
1.4.4 Latin America Recombinant FVIII Sales Breakdown by Type (2018-2023)
1.4.5 Middle East and Africa Recombinant FVIII Sales Breakdown by Type (2018-2023)
2 Global Recombinant FVIII Market Competition by Company
2.1 Global Top Players by Recombinant FVIII Sales (2018-2023)
2.2 Global Top Players by Recombinant FVIII Revenue (2018-2023)
2.3 Global Top Players by Recombinant FVIII Price (2018-2023)
2.4 Global Top Manufacturers Recombinant FVIII Manufacturing Base Distribution, Sales Area, Product Type
2.5 Recombinant FVIII Market Competitive Situation and Trends
2.5.1 Recombinant FVIII Market Concentration Rate (2018-2023)
2.5.2 Global 5 and 10 Largest Manufacturers by Recombinant FVIII Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Recombinant FVIII as of 2022)
2.7 Date of Key Manufacturers Enter into Recombinant FVIII Market
2.8 Key Manufacturers Recombinant FVIII Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Recombinant FVIII Status and Outlook by Region
3.1 Global Recombinant FVIII Market Size and CAGR by Region: 2018 VS 2022 VS 2029
3.2 Global Recombinant FVIII Historic Market Size by Region
3.2.1 Global Recombinant FVIII Sales in Volume by Region (2018-2023)
3.2.2 Global Recombinant FVIII Sales in Value by Region (2018-2023)
3.2.3 Global Recombinant FVIII Sales (Volume & Value) Price and Gross Margin (2018-2023)
3.3 Global Recombinant FVIII Forecasted Market Size by Region
3.3.1 Global Recombinant FVIII Sales in Volume by Region (2024-2029)
3.3.2 Global Recombinant FVIII Sales in Value by Region (2024-2029)
3.3.3 Global Recombinant FVIII Sales (Volume & Value), Price and Gross Margin (2024-2029)
4 Global Recombinant FVIII by Application
4.1 Recombinant FVIII Market Segment by Application
4.1.1 Teenagers
4.1.2 Adults
4.2 Global Recombinant FVIII Market Size by Application
4.2.1 Global Recombinant FVIII Market Size Overview by Application (2018-2029)
4.2.2 Global Recombinant FVIII Historic Market Size Review by Application (2018-2023)
4.2.3 Global Recombinant FVIII Forecasted Market Size by Application (2024-2029)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Recombinant FVIII Sales Breakdown by Application (2018-2023)
4.3.2 Europe Recombinant FVIII Sales Breakdown by Application (2018-2023)
4.3.3 Asia-Pacific Recombinant FVIII Sales Breakdown by Application (2018-2023)
4.3.4 Latin America Recombinant FVIII Sales Breakdown by Application (2018-2023)
4.3.5 Middle East and Africa Recombinant FVIII Sales Breakdown by Application (2018-2023)
5 North America Recombinant FVIII by Country
5.1 North America Recombinant FVIII Historic Market Size by Country
5.1.1 North America Recombinant FVIII Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
5.1.2 North America Recombinant FVIII Sales in Volume by Country (2018-2023)
5.1.3 North America Recombinant FVIII Sales in Value by Country (2018-2023)
5.2 North America Recombinant FVIII Forecasted Market Size by Country
5.2.1 North America Recombinant FVIII Sales in Volume by Country (2024-2029)
5.2.2 North America Recombinant FVIII Sales in Value by Country (2024-2029)
6 Europe Recombinant FVIII by Country
6.1 Europe Recombinant FVIII Historic Market Size by Country
6.1.1 Europe Recombinant FVIII Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
6.1.2 Europe Recombinant FVIII Sales in Volume by Country (2018-2023)
6.1.3 Europe Recombinant FVIII Sales in Value by Country (2018-2023)
6.2 Europe Recombinant FVIII Forecasted Market Size by Country
6.2.1 Europe Recombinant FVIII Sales in Volume by Country (2024-2029)
6.2.2 Europe Recombinant FVIII Sales in Value by Country (2024-2029)
7 Asia-Pacific Recombinant FVIII by Region
7.1 Asia-Pacific Recombinant FVIII Historic Market Size by Region
7.1.1 Asia-Pacific Recombinant FVIII Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029
7.1.2 Asia-Pacific Recombinant FVIII Sales in Volume by Region (2018-2023)
7.1.3 Asia-Pacific Recombinant FVIII Sales in Value by Region (2018-2023)
7.2 Asia-Pacific Recombinant FVIII Forecasted Market Size by Region
7.2.1 Asia-Pacific Recombinant FVIII Sales in Volume by Region (2024-2029)
7.2.2 Asia-Pacific Recombinant FVIII Sales in Value by Region (2024-2029)
8 Latin America Recombinant FVIII by Country
8.1 Latin America Recombinant FVIII Historic Market Size by Country
8.1.1 Latin America Recombinant FVIII Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
8.1.2 Latin America Recombinant FVIII Sales in Volume by Country (2018-2023)
8.1.3 Latin America Recombinant FVIII Sales in Value by Country (2018-2023)
8.2 Latin America Recombinant FVIII Forecasted Market Size by Country
8.2.1 Latin America Recombinant FVIII Sales in Volume by Country (2024-2029)
8.2.2 Latin America Recombinant FVIII Sales in Value by Country (2024-2029)
9 Middle East and Africa Recombinant FVIII by Country
9.1 Middle East and Africa Recombinant FVIII Historic Market Size by Country
9.1.1 Middle East and Africa Recombinant FVIII Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
9.1.2 Middle East and Africa Recombinant FVIII Sales in Volume by Country (2018-2023)
9.1.3 Middle East and Africa Recombinant FVIII Sales in Value by Country (2018-2023)
9.2 Middle East and Africa Recombinant FVIII Forecasted Market Size by Country
9.2.1 Middle East and Africa Recombinant FVIII Sales in Volume by Country (2024-2029)
9.2.2 Middle East and Africa Recombinant FVIII Sales in Value by Country (2024-2029)
10 Company Profiles
10.1 Bayer
10.1.1 Bayer Company Information
10.1.2 Bayer Introduction and Business Overview
10.1.3 Bayer Recombinant FVIII Sales, Revenue and Gross Margin (2018-2023)
10.1.4 Bayer Recombinant FVIII Products Offered
10.1.5 Bayer Recent Development
10.2 Baxter
10.2.1 Baxter Company Information
10.2.2 Baxter Introduction and Business Overview
10.2.3 Baxter Recombinant FVIII Sales, Revenue and Gross Margin (2018-2023)
10.2.4 Baxter Recombinant FVIII Products Offered
10.2.5 Baxter Recent Development
10.3 Comirnaty
10.3.1 Comirnaty Company Information
10.3.2 Comirnaty Introduction and Business Overview
10.3.3 Comirnaty Recombinant FVIII Sales, Revenue and Gross Margin (2018-2023)
10.3.4 Comirnaty Recombinant FVIII Products Offered
10.3.5 Comirnaty Recent Development
10.4 Novo Nordisk
10.4.1 Novo Nordisk Company Information
10.4.2 Novo Nordisk Introduction and Business Overview
10.4.3 Novo Nordisk Recombinant FVIII Sales, Revenue and Gross Margin (2018-2023)
10.4.4 Novo Nordisk Recombinant FVIII Products Offered
10.4.5 Novo Nordisk Recent Development
10.5 Green Cross
10.5.1 Green Cross Company Information
10.5.2 Green Cross Introduction and Business Overview
10.5.3 Green Cross Recombinant FVIII Sales, Revenue and Gross Margin (2018-2023)
10.5.4 Green Cross Recombinant FVIII Products Offered
10.5.5 Green Cross Recent Development
10.6 Sinocelltech
10.6.1 Sinocelltech Company Information
10.6.2 Sinocelltech Introduction and Business Overview
10.6.3 Sinocelltech Recombinant FVIII Sales, Revenue and Gross Margin (2018-2023)
10.6.4 Sinocelltech Recombinant FVIII Products Offered
10.6.5 Sinocelltech Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Recombinant FVIII Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Recombinant FVIII Industrial Chain Analysis
11.4 Recombinant FVIII Market Dynamics
11.4.1 Recombinant FVIII Industry Trends
11.4.2 Recombinant FVIII Market Drivers
11.4.3 Recombinant FVIII Market Challenges
11.4.4 Recombinant FVIII Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Recombinant FVIII Distributors
12.3 Recombinant FVIII Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
